The effect of thymoquinone on the renal functions following ischemia-reperfusion injury in the rat

International Journal of Physiology, Pathophysiology and Pharmacology

Volumn 8, Issue 4, 2016, Pages 152-159

  Hammad, Fayez T ^a   Lubbad, Loay ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Ischemia reperfusion injury; Renal functions; Thymoquinone

Indexed keywords

THYMOQUINONE;

ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HEART RATE; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; NONHUMAN; RAT; REAL TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY; RNA EXTRACTION;

EID: 85008411795     PISSN: None     EISSN: 19448171     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Chatauret N, Badet L, Barrou B, Hauet T. Ischemia-reperfusion: from cell biology to acute kidney injury. Prog Urol 2014; 24 Suppl 1: S4-12.
2. Hammad FT, Davis G, Zhang XY, Wheatley AM. Endotelin ETA and ETB receptor antagonism during cold preservation in renal transplantation. Transplantation 2001; 71: 619-27.
3. Lerman L and Textor SC. Pathophysiology of ischemic nephropathy. Urol Clin North Am 2001; 28: 793-803, ix.
4. Furuichi K, Wada T, Kaneko S, Murphy PM. Roles of chemokines in renal ischemia/reperfusion injury. Front Biosci 2008; 13: 4021-8.
5. Weight SC, Bell PR and Nicholson ML. Renal ischaemia--reperfusion injury. Br J Surg 1996; 83: 162-70.
6. Touijer K, Jacqmin D, Kavoussi LR, Montorsi F, Patard JJ, Rogers CG, Russo P, Uzzo RG, Van Poppel H. The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. Eur Urol 2010; 57: 214-22.
7. Uzzo RG and Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 2001; 166: 6-18.
8. Rodrigue JR, Cornell DL, Lin JK, Kaplan B, Howard RJ. Increasing live donor kidney transplantation: a randomized controlled trial of a home-based educational intervention. Am J Transplant 2007; 7: 394-401.
9. Vuorelaa P, Leinonenb M, Saikkuc P, Tammelaa P, Rauhad JP, Wennberge T, Vuorela H. Natural products in the process of finding new drug candidates. Curr Med Chem 2004; 11: 1375-89.
10. Gali-Muhtasib H, Roessner A, Schneider-Stock R. Thymoquinone: a promising anti-cancer drug from natural sources. Int J Biochem Cell Biol 2006; 38: 1249-53.
11. El-Dakhakhny M. Studies on the chemical constitution of Egyptian N. sativa L. seeds. Planta Med 1963; 11: 465-70.
12. Awad AS, Kamel R, Sherief MA. Effect of thymoquinone on hepatorenal dysfunction and alteration of CYP3A1 and spermidine/spermine N-1-acetyl-transferase gene expression induced by renal ischaemia-reperfusion in rats. J Pharm Pharmacol 2011; 63: 1037-42.
13. Farag MM, Ahmed GO, Shehata RR, Kazem AH. Thymoquinone improves the kidney and liver changes induced by chronic cyclosporine A treatment and acute renal ischaemia/reperfusion in rats. J Pharm Pharmacol 2015; 67: 731-9.
14. Mansour MA, Nagi MN, El-Khatib AS, Al-Bekairi AM. Effects of thymoquinone on antioxidant enzyme activities, lipid peroxidation and DT-diaphorase in different tissues of mice: a possible mechanism of action. Cell Biochem Funct 2002; 20: 143-51.
15. Banerjee S, Kaseb AO, Wang Z, Kong D, Mo-hammad M, Padhye S, Sarkar FH, Mohammad RM. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res 2009; 69: 5575-83.
16. Chehl N, Chipitsyna G, Gong Q, Yeo CJ, Arafat HA. Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells. HPB (Oxford) 2009; 11: 373-81.
17. El Gazzar MA, El Mezayen R, Nicolls MR, Dres-kin SC. Thymoquinone attenuates proinflammatory responses in lipopolysaccharide-activated mast cells by modulating NF-kappaB nuclear transactivation. Biochim Biophys Acta 2007; 1770: 556-64.
18. Elsherbiny NM and El-Sherbiny M. Thymo-quinone attenuates Doxorubicin-induced ne-phrotoxicity in rats: role of Nrf2 and NOX4. Chem Biol Interact 2014; 223: 102-8.
19. Li F, Rajendran P and Sethi G. Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transdu-cer and activator of transcription 3 activation pathway. Br J Pharmacol 2010; 161: 541-54.
20. Rajput S, Kumar BN, Banik P, Parida S, Mandal M. Thymoquinone restores radiation-induced TGF-beta expression and abrogates EMT in chemoradiotherapy of breast cancer cells. J Cell Physiol 2015; 230: 620-9.
21. Samarghandian S, Azimi-Nezhad M, Mehrad-Majd H, Mirhafez SR. Thymoquinone ameliorates acute renal failure in gentamicin-treated adult male rats. Pharmacology 2015; 96: 112-7.
22. Fouda AM, Daba MH, Dahab GM, Sharaf El-Din OA. Thymoquinone ameliorates renal oxidative damage and proliferative response induced by mercuric chloride in rats. Basic Clin Pharmacol Toxicol 2008; 103: 109-18.
23. Hadjzadeh MA, Mohammadian N, Rahmani Z, Rassouli FB. Effect of thymoquinone on ethylene glycol-induced kidney calculi in rats. Urol J 2008; 5: 149-55.
24. Kanter M. Protective effects of thymoquinone on streptozotocin-induced diabetic nephropathy. J Mol Histol 2009; 40: 107-15.
25. Sayed-Ahmed MM and Nagi MN. Thymoquinone supplementation prevents the development of gentamicin-induced acute renal toxicity in rats. Clin Exp Pharmacol Physiol 2007; 34: 399-405.
26. Stevens LA, Coresh J, Greene T, Levey AS. As-sessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-83.
27. Hammad FT, Al-Salam S and Lubbad L. Cur-cumin provides incomplete protection of the kidney in ischemia reperfusion injury. Physiol Res 2012; 61: 503-11.
28. Hammad FT, Al-Salam S and Lubbad L. Does aliskiren protect the kidney following ischemia reperfusion injury? Physiol Res 2013; 62: 681-90.
29. Spurgeon KR, Donohoe DL and Basile DP. Transforming growth factor-beta in acute renal failure: receptor expression, effects on pro-liferation, cellularity, and vascularization after recovery from injury. Am J Physiol Renal Physiol 2005; 288: F568-77.
30. Speeckaert MM, Speeckaert R, Laute M, Van-holder R, Delanghe JR. Tumor necrosis factor receptors: biology and therapeutic potential in kidney diseases. Am J Nephrol 2012; 36: 261-70.
31. Ding Y and Choi ME. Regulation of autophagy by TGF-beta: emerging role in kidney fibrosis. Semin Nephrol 2014; 34: 62-71.
32. Chorostowska-Wynimko J, Swiercz R, Skrzy-pczak-Jankun E, Wojtowicz A, Selman SH, Jan-kun J. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Mol Cancer Ther 2003; 2: 19-28.
33. Ghosh AK and Vaughan DE. PAI-1 in tissue fibrosis. J Cell Physiol 2012; 227: 493-507.
34. Lim AI, Tang SC, Lai KN, Leung JC. Kidney injury molecule-1: more than just an injury marker of tubular epithelial cells? J Cell Physiol 2013; 228: 917-24.
35. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003; 14: 2534-43.